ID | 118571 |
著者 |
Kadota, Naoki
National Hospital Organization Kochi Hospital
Hatakeyama, Nobuo
National Hospital Organization Kochi Hospital
Hino, Hiroyuki
National Hospital Organization Kochi Hospital
國重, 道大
National Hospital Organization Kochi Hospital
Kondo, Yoshihiro
National Hospital Organization Kochi Hospital
Okano, Yoshio
National Hospital Organization Kochi Hospital
Machida, Hisanori
National Hospital Organization Kochi Hospital
Naruse, Keishi
National Hospital Organization Kochi Hospital
Ogushi, Fumitaka
National Hospital Organization Kochi Hospital
Takeuchi, Eiji
National Hospital Organization Kochi Hospital
|
キーワード | complete response
immune checkpoint inhibitor
pembrolizumab
plasma cell
pulmonary large cell neuroendocrine carcinoma
|
資料タイプ |
学術雑誌論文
|
抄録 | Background: Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare and aggressive tumor with a poor prognosis and standard therapy has not yet been established.
Case: A 65-year-old male with a cough for 2 months presented to our hospital. He was clinically diagnosed with non small cell lung cancer cT3N1M0 stage IIIA and underwent right pneumonectomy. The final diagnosis was pulmonary LCNEC pT3N1M0 stage IIIA. Multiple subcutaneous masses were detected 4 months after surgery, and biopsy revealed postoperative recurrence and metastasis. Chemotherapy with carboplatin plus etoposide was initiated. Subcutaneous masses increased and multiple new brain metastases developed after two cycles. Additional tests revealed that epidermal growth factor receptor and anaplastic lymphoma kinase were negative, and the programmed death ligand 1 (PD-L1) expression rate in tumor cells was 40% (22C3 clones). The primary cells infiltrating the tumor were CD3-positive T cells and CD138-positive plasma cells. Second-line treatment with pembrolizumab was started. The shrinkage of subcutaneous masses was observed after one cycle, and the tumor had completely disappeared after six cycles. Treatment was continued for approximately 2 years. This response has been maintained for 4 years and is still ongoing. Conclusion: Pembrolizumab may be used as a treatment option for pulmonary LCNEC. |
掲載誌名 |
Cancer Reports
|
ISSN | 25738348
|
出版者 | Wiley Periodicals
|
巻 | 5
|
号 | 8
|
開始ページ | e1589
|
発行日 | 2021-11-24
|
権利情報 | This is an open access article under the terms of the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
|
EDB ID | |
出版社版DOI | |
出版社版URL | |
フルテキストファイル | |
言語 |
eng
|
著者版フラグ |
出版社版
|
部局 |
医学系
|